Multidisciplinary Etiologic Study of Familial Testicular Cancer
Testicular germ cell tumors (TGCT) is the most common cancer in men aged 20-35, with an
increasing incidence since the mid-twentieth century.
A family history of TGCT is associated with an increased risk of the disease.
Evidence suggests that there is genetic heterogeneity in familial TGCT, thereby creating
opportunities for both new susceptibility gene discovery and searching for
Search for genitourinary developmental anomalies and for testicular intraepithelial
neoplasia (TIN) cells which are thought to be the precursor of the vast majority of TGCT
could help clarify the etiology and identify clinical features.
This project is both etiologic and clinical in its focus, and its goal is to acquire a
comprehensive understanding of both the genetic and non-genetic factors which contribute to
the risk of familial TGCT.
Ascertain new families with familial testicular germ cell tumors.
Characterize the clinical features of familial TGCT.
Determine the underlying genetic mechanism for susceptibility to TGCT in families; one
specific goal is to confirm, and then to clone, the hereditary testicular cancer gene which
has been mapped to chromosome Xq27.
Evaluate various parameters related to psychosocial and behavioral issues resulting from
being a member of a family at increased risk of TGCT.
A single family member with bilateral testicular cancer.
Individuals of both genders from a family with at least two cases of documented GCT in blood
relatives (at least one of which is testicular in origin) and with at least one of the GCT
cases in their family willing to participate in the study.
Men with a history of TGCT who have a monozygotic twin brother (the unaffected identical
sibling must also agree to participate).
Families will be deemed ineligible if critical informative family members lacking surviving
spouses and children are unable to provide germ line DNA
Minor children under age 12 will not be eligible for study participation.
International collaboration between NCI's Clinical Genetics Branch and the International
Testicular Cancer Linkage Consortium (ITCLC), via contribution of DNA.
Non-randomized cohort study with an estimated accrual of 75 and 100 new TGCT families over a
period of 5 years and approximately 40 families willing to visit the NIH Clinical Center.
Individuals and family members will be asked to contribute baseline questionnaires as well
as questionnaires regarding lifestyle, feelings, attitudes and behavior that relate to being
part of a high-risk family, and DNA for gene mapping and cloning efforts.
Detailed, in-person, etiologically-oriented evaluation at the NIH Clinical Center includes a
comprehensive history and physical examination, laboratory testing, and ultrasound imaging
of the kidneys and gonads to identify the clinical features and seek clinically occult TGCT
and TIN. CT imaging studies of the chest, abdomen, and pelvis will be performed when
Study participants will be monitored prospectively for the development of outcomes of
interest by means of periodic mail and/or telephone contact. Cancer outcomes will be
documented through review of medical, vital, and pathology records. Tumor tissue will be
obtained whenever feasible.
Jennifer T Loud, C.R.N.P.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|